137 related articles for article (PubMed ID: 31730591)
1. Management of patients with relapsed/refractory metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):14-16. PubMed ID: 31730591
[No Abstract] [Full Text] [Related]
2. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
[No Abstract] [Full Text] [Related]
3. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
Rutherford SC; Leonard JP
JAMA Oncol; 2018 Aug; 4(8):1120-1121. PubMed ID: 30003234
[No Abstract] [Full Text] [Related]
4. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
5. Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.
Isoda A; Ishikawa T; Miyazawa Y; Mihara M; Matsumoto M; Sawamura M
Leuk Lymphoma; 2018 May; 59(5):1277-1278. PubMed ID: 28874073
[No Abstract] [Full Text] [Related]
6. 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Podolsky L; Oh M; Subbarayan PR; Francheschi D; Livingstone A; Ardalan B
Acta Oncol; 2011 May; 50(4):602-5. PubMed ID: 20950119
[No Abstract] [Full Text] [Related]
7. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Goldberg R
Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
[No Abstract] [Full Text] [Related]
8. Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations.
Grothey A; Marshall JL; Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):16-18. PubMed ID: 31730592
[No Abstract] [Full Text] [Related]
9. Options for patients with metastatic colorectal cancer who progress after second-line therapy.
Marshall JL
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589
[No Abstract] [Full Text] [Related]
10. New hope for relapsed and refractory multiple myeloma.
Leleu X
Lancet Oncol; 2013 Oct; 14(11):1028-1029. PubMed ID: 24007745
[No Abstract] [Full Text] [Related]
11. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
[No Abstract] [Full Text] [Related]
12. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M
Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787
[No Abstract] [Full Text] [Related]
14. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
16. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer.
Tyagi P
Clin Colorectal Cancer; 2005 May; 5(1):21-3. PubMed ID: 15929802
[No Abstract] [Full Text] [Related]
17. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
20. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
[Next] [New Search]